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The high efficiency of gene transfer into cells ex vivo is conducive to therapeutic applications. Hence, it was not surprising that the first gene transfer studies in man were performed with genetically engineered cellular autografts. 2 More recently, the Food and Drug Administration approved the first dendritic cell immunotherapy for cancer (http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm210174.htm). This portends future regulatory approvals for gene therapy applications employing genetically modified dendritic cells, which is the topic of many original research and review articles previously published in Cancer Gene Therapy. Concurrently, identification and applications of pleuripotent progenitor cells in a wide variety of tissues have expanded significantly.
The past and present predict a bright future for numerous and varied applications of combined cellular and gene therapy products. Advances in cellular therapies will improve ipso facto their genetically modified counterparts. Hence, this issue of Cancer Gene Therapy marks the first bearing its new subtitle 'The Journal of Cancer Gene and Cellular Therapies', reflecting the broader scope of articles that the Journal will publish to advance the development of these emerging and converging disciplines.
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